Precision oncology for breast cancer through clinical trials

Precision treatment for breast cancers has made several notable advances in recent decades, but challenges of tumor heterogeneity, drug resistance, and aggressive recurrence and metastases remain. To meet and overcome these challenges, we must refine our understanding of breast subtypes and treatmen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical & experimental metastasis Ročník 39; číslo 1; s. 71 - 78
Hlavní autoři: Blucher, Aurora S., Mills, Gordon B., Tsang, Yiu Huen
Médium: Journal Article
Jazyk:angličtina
Vydáno: Dordrecht Springer Netherlands 01.02.2022
Springer Nature B.V
Témata:
Biomarkers
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Cancer Research
Chemotherapy
Clinical trials
Drug resistance
Female
Hematology
Heterogeneity
Humans
Immunotherapy
Medical Oncology
Metastases
Oncology
Precision medicine
Precision Medicine - methods
Review
Surgical Oncology
Tumors
Precision medicine
Targeted therapy
Transcriptomics
Genomics
Proteomics
Biomarkers
Clinical trials
Breast cancer
ISSN:0262-0898, 1573-7276, 1573-7276
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Precision treatment for breast cancers has made several notable advances in recent decades, but challenges of tumor heterogeneity, drug resistance, and aggressive recurrence and metastases remain. To meet and overcome these challenges, we must refine our understanding of breast subtypes and treatment biomarkers according to the knowledge afforded across the spectrum of ‘omics assays. A critical aspect of harnessing this knowledge into actionable biomarkers for treatment decision relies on our ability to integrate knowledge across data types and leverage our insight in evidence-based clinical trials. We review recent advances in cutting-edge clinical trials for precision treatment of breast cancer, including chemotherapies, targeted therapies, immunotherapies, and combination therapies. We comment on promising future areas of development for this exciting point in precision breast cancer research.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0262-0898
1573-7276
1573-7276
DOI:10.1007/s10585-021-10092-0